Cipla share news, announcements and annual reports
NSE: CIPLABSE: 500087Pharmaceuticals & BiotechnologyLarge Cap
Cipla Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1983 on BSE, Feb 1995 on NSE
Last close ₹1,378.90up ₹20.90 (1.54%)BSE ₹1,380.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,358.00.
30 Oct: open ₹1,362.00, high ₹1,381.70, low ₹1,357.00
52-week range of traded prices to 30 Oct 2026
₹1,165.70Low, 2 Apr 2026₹1,593.30High, 30 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,11,397 Cr99th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.45
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.15
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.94%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 9.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 14,36,66155.4% delivered
Cipla share news and announcements
1,563 announcements, routine notices left out, newest first. Page 30 of 32.
Dec 2010
20 Dec · Legal
Company have issued the below statement to wire agencies regarding clarification on Cipla's stake sale. "The speculative news on stake sale of Cipla or any of its brand is baseless and therefore denied."9 Dec · Management
Contract of Mr. Amar Lulla as Joint Managing Director of the Company will expire on December 13, 2010. Mr. Amar Lulla has informed the Company that he is not in a position to continue his services in the above capacity on expiry of his current term. In deference of his wishes, the Board has accepted his request. Consequently Mr Amar Lulla will cease to be the joint Managing Director of the Company effective from the aforesaid date. The Company would like to place on record its sincere appreciation and gratitude to Mr. Amar Lulla for his pioneering efforts during his association with the Company for over three decades. He has been one of the key persons who has played a significant role in enabling the company to attain its current position.
Nov 2010
11 Nov · Updates
11 Nov · Management
Board of Directors of the Company at its meeting held on November 11, 2010, have appointed Mr.S.Radhakrishnan as an Additional Director and Whole-time Director of the Company for a period of 5 years. Mr.S.Radhakrishnan is a qualified Chartered Accountant, has been with the Company for over 26 years and has rich experience in financial, commercial, legal and allied areas.11 Nov · Management
Mr. S. A. A. Pinto, Director has resigned from the Directorship of the Company due to health reasons.11 Nov · Results
Standalone Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 157988 lacs for quarter ending on 30-SEP-2010 against Rs. 137118 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 26301 lacs for the quarter ending on 30-SEP-2010 against Rs. 27574 lacs for the quarter ending on 30-SEP-2009.3 Nov · Board meeting
Inter-alia to consider Unaudited Financial Results for Second quarter ended September 30, 2010.
Aug 2010
31 Aug · Dividend
Date of payment of special interim dividend for the financial year ending March 31, 2011 would be on or before September 24, 2010.27 Aug · Meeting
At the Annual General Meeting of the Members of the Company held on August 25, 2010, all resolutions were passed with requisite majority. A brief summary of the resolutions passed at the Annual General Meeting are as under: (1) Balance Sheet as at March 31, 2010, the Profit and Loss Account for the year ended on that date together with the schedules annexed thereto as well as the reports of the Board of Directors and Auditors thereon were adopted. (2) Dividend at the rate of 100% on 80,29,21,357 Equity Shares of Rs.2/- each for the financial year ended March 31, 2010 was declared. (3) Dr. H.R. Manchanda has been re-appointed as Director of the Company. (4) Mr. Ramesh Shroff has been re-appointed as Director of the Company.(5) M/s R.G.N. Price & Co. Chartered Accountants together with M/s. V. Sankar Aiyar & Co., Chartered Accountants have been re-appointed as Joint Statutory Auditors of the Company. Special Business: (6) Special Resolution for appointment of Mr. Kamil Hamied as a member of Management team of the Company was approved.25 Aug · Corporate action
Board of Directors of the Company have fixed September 06, 2010 as the Record Date for determining the shareholders who will be entitled to receive the interim dividend.25 Aug · Dividend
Board of Directors of the Company at its meeting held on August 25, 2010, inter-alia, has declared a special interim dividend of 80 paise per equity share (face value of Rs. 2/- per share) for the financial year ending March 31, 2011 to commemorate 75th Anniversary of the Company. The total payout inclusive of dividend tax would aggregate of approx Rs. 75 Crores.23 Aug · Board meeting
Inter-alia to consider special interim dividend for the financial year 2010-2011 to commemorate 75th Anniversary of the Company.13 Aug · Updates
13 Aug · Results
Standalone Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 142738 lacs for quarter ending on 30-JUN-2010 against Rs. 132526 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 25742 lacs for the quarter ending on 30-JUN-2010 against Rs. 24171 lacs for the quarter ending on 30-JUN-2009.11 Aug · Updates
Dividend warrants for the year 2009-2010 will be dated on or about September 01, 2010 and will be dispatched to the shareholders within the stipulated time limit.5 Aug · Meeting
Annual General Meeting of the Company will be held on August 25, 2010.5 Aug · Board meeting
Inter-alia to consider Unaudited Financial Results for first quarter ended June 30, 2010.
Jul 2010
9 Jul · Legal
Vide its letter dated July 09, 2010 that "With reference to the news item appearing in today's newspaper titled "Cipla brass to get new shine, CEO to step down". At the outset we would like to inform you that the contents of the news items are speculative. We wish to clarify that Mr. Amar Lulla is on medical leave. The Board is fully seized of the matter and will take appropriate steps as and when needed."
Jun 2010
15 Jun · Corporate action
Register of Members and the Share Transfer Books of the Company shall remain closed from July 27, 2010 to July 30, 2010 (both days inclusive) for the purpose of Annual General Meeting and determining the persons entitled for dividend for the year ended March 31, 2010.15 Jun · Board meeting
Board of Directors at its meeting held on June 15, 2010 have inter-alia approved the following investment in 2 Biotech Companies with a joint venture partner in China: (1) Acquisition of 40% stake in a biotech company based in India through subscription of fresh shares of the company. The biotech company is setting up a state of the art facility for biosimilar products in Goa. Cipla will have rights to market all biosimilar products of the company in India and in international markets; (2) Acquisition of 25% stake in a biotech company in Hong Kong through subscription of fresh shares of the company. The investment will be made by Cipla through a wholly owned overseas subsidiary. The biotech company is setting up a state of the art facility for biosimilar products in Shanghai, China through its wholly owned subsidiary. Cipla will have rights to market biosimilar products of this biotech company in India and in international markets. The total investment for both the aforesaid biotech companies is estimated to be about USD 65 million in a phased manner over a period of 3 years.15 Jun · Dividend
Directors of the Company at their meeting held on June 15, 2010 recommended payment of dividend of Rs.2 per equity share (face value Rs. 2) for the year 2009-2010 amounting to Rs. 160.58 crores.15 Jun · Results
Consolidated Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 535952 lacs for year ending on 31-MAR-2010 against Rs. 496060 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 108259 lacs for the year ending on 31-MAR-2010 against Rs. 77102 lacs for the year ending on 31-MAR-2009.15 Jun · Results
Standalone Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 535952 lacs for year ending on 31-MAR-2010 against Rs. 496060 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 108149 lacs for the year ending on 31-MAR-2010 against Rs. 77682 lacs for the year ending on 31-MAR-2009.7 Jun · Board meeting
Inter-alia to consider the Annual Audited Accounts for the year ended March 31, 2010 and Recommendation of Dividend, if any.
May 2010
24 May · Updates
Company has set up a Wholly Owned Subsidiary 'Cipla Singapore Pte Limited' in Singapore. The subsidiary has been set up inter-alia to aid logistics and distribution of Company's export business.7 May · Business
Board of Directors of the Company at its meeting held on May 07, 2010 have inter alia approved the acquisition of two manufacturing facilities which hitherto were manufacturing formulations and bulk drugs/ intermediates exclusively for the Company for an aggregate consideration of Rs. 82.02 crores as follows: (i) Acquisition of a Company for Rs. 51.38 crores, which has a state of the art formulations manufacturing facility at Sikkim with capabilities to manufacture Tablets, Capsules, Oral liquids, Injections, Liquid and Ointments/ Creams. The Company is eligible for a 10 year tax holiday under the Income Tax Act, 1961 commencing from the financial year 2009-10. (ii) Acquisition of undertaking for Rs. 30.64 crores, by way of slump sale arrangement. The undertaking is located at Kurkumbh (District Pune) and has US FDA & WHO approved manufacturing facility for bulk drugs / intermediates. These acquisitions are being done with an objective to exercise control over operations of these facilities. Entities controlled by relatives of the promoters are major shareholders in the Company / facilities proposed to be acquired. The aggregate consideration for both acquisitions was determined on the basis of valuation reports provided by Grant Thornton and fairness opinions provided by Kotak Mahindra Capital Company Limited.7 May · Updates
7 May · Results
Standalone Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 131749 lacs for quarter ending on 31-MAR-2010 against Rs. 123517 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 27553 lacs for the quarter ending on 31-MAR-2010 against Rs. 25292 lacs for the quarter ending on 31-MAR-2009.
Apr 2010
29 Apr · Board meeting
Meeting on 7 May 2010: “Unaudited Financial Results for the qtr ended March 31, 2010”
Mar 2010
23 Mar · Business
Cipla Ltd. has informed the Exchange regarding a press release dated March 23, 2010, titled "Piramal Healthcare Limited Acquires "i-pill", India's No 1 Emergency Contraceptive Brand from Cipla Ltd.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2010
28 Jan · Updates
Cipla Ltd. has submitted to the Exchange a copy of the Financial Review - Period ended December 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Jan · Results
Cipla Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 134416 lacs for quarter ending on 31-DEC-2009 against Rs. 126430 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 28903 lacs for the quarter ending on 31-DEC-2009 against Rs. 22344 lacs for the quarter ending on 31-DEC-2008.20 Jan · Board meeting
Meeting on 28 Jan 2010: “Unaudited Financial Results for the qtr ended Dec 31, 2009”
Dec 2009
7 Dec · Updates
Cipla Ltd. has informed the Exchange that "This has reference to our earlier disclosures regarding notices received by the Company from the National Pharmaceutical Pricing Authority, Government of India. The Company has now received further demand notices from the Government as under: (i) demand notice demanding an amount of Rs. 201.40 million comprising allegedly overcharged amount of Rs 115.49 million and interest thereon of Rs. 85.91 million in respect of the drug Ciprofloxacin. The period to which these amounts pertain to have not been specified in the demand notice. (ii) demand notice demanding an amount of Rs. 0.11 million comprising interest up to April 2009 in respect of the drug Doxycycline. These demands are contrary to the orders of the Hon'ble Supreme Court of India and the Company has received legal advice that entire amounts demanded by the Government are not tenable and sustainable".
Oct 2009
28 Oct · Updates
Cipla Ltd. has submitted to the Exchange a copy of the Financial Review - Period ended September 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Oct · Results
Cipla Ltd. has informed the Exchange regarding the standalone Results for the half year ended on 30-SEP-2009 as follows: Net Sales of Rs. 269644 lacs for half year ending on 30-SEP-2009 against Rs. 247322 lacs for the half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 51745 lacs for the half year ending on 30-SEP-2009 against Rs. 29147 lacs for the half year ending on 30-SEP-2008.28 Oct · Results
Cipla Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 137118 lacs for quarter ending on 30-SEP-2009 against Rs. 130246 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 27574 lacs for the quarter ending on 30-SEP-2009 against Rs. 15143 lacs for the quarter ending on 30-SEP-2008.20 Oct · Board meeting
Meeting on 28 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009”
Sep 2009
29 Sep · Business
Cipla Ltd. has informed the Exchange that "The duly authorized Committee of Directors of the Company at its meeting held today i.e. on September 29, 2009 , at Hyderabad has issued and allotted 2,56,30,000 fully paid-up equity Shares of Rs. 2 each ("Equity Share") at an issue price of Rs.263.75 per Equity Share (including a premium of Rs.261.75 per Equity Share) aggregating to Rs.6,75,99,12,500 to qualified institutional bidders by way of a qualified institutions placement in terms of Chapter VIII of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009".25 Sep · Business
Cipla Ltd. has informed the Exchange that "The duly authorized Committee of Directors of the Company at its meeting held today i.e. on September 24, 2009 has decided to close the bid period and has approved issuance of 2,56,30,000 Equity Shares of Rs. 2 each of the Company at a price of Rs. 263.75 per Equity Share (including a premium of Rs. 261.75 per equity share) under the QIP issue, aggregating to Rs. 6,75,99,12,500/-. The Committee has also approved the Placement Document in respect of the Equity Shares proposed to be issued as aforesaid."
Aug 2009
28 Aug · Meeting
Cipla Ltd. has informed the Exchange that at the Annual General Meeting of the Members of the Company held on August 26, 2009 all resolutions (as per attachment) were passed unanimously. The details of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements) For more details click here.13 Aug · Meeting
Cipla Ltd. has informed the Exchange that the Annual General Meeting of the members of the Company will be held on August 26, 2009.
Jul 2009
29 Jul · Updates
Cipla Ltd. has submitted to the Exchange a copy of the note displayed on Company's website www.cipla.com titled "Financial Review- Period ended June 2009". A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Jul · Raising of Funds
Cipla Ltd. has informed the Exchange that the Board of Directors of the Company at its meeting held on July 29, 2009 inter-alia approved the notice convening Annual General Meeting including an enabling resolution to raise funds upto Rs. 1500 crores subject to shareholders and other necessary approvals by further issue of securities in domestic/international markets through various instruments including equity shares/warrants with Non-Convertible Debentures under Qualified Institutions Placement (QIP) or Foreign Currency Convertible Bonds (FCCBs) or American Depository Receipts (ADRs) or Global Depository Receipts (GDRs) etc.29 Jul · Results
Cipla Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 132526 lacs for quarter ending on 30-JUN-2009 against Rs. 120712 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 24171 lacs for the quarter ending on 30-JUN-2009 against Rs. 14004 lacs for the quarter ending on 30-JUN-2008.21 Jul · Board meeting
Meeting on 29 Jul 2009: “Unaudited Financial Results for the Qtr ended June 30, 2009/Unaudited Financial Results/Raising of funds/Others”